Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Interferon gamma + Peginterferon alfa-2b |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Interferon gamma | Actimmune | gamma interferon|IFN-G|recombinant interferon gamma | Interferon gamma is a cytokine that binds IFN-gamma receptors, leading to pleiotropic effects, including stimulating antibody-dependent cytotoxicity and enhanced natural killer cell activity against tumor cells and the activation of caspases, leading to apoptosis of malignant cells (PMID: 14525967). | |
Peginterferon alfa-2b | Sylatron | PEG-IFN | Sylatron (peginterferon alfa-2b) is polyethylene glycol (PEG)-conjugated recombinant interferon alpha, subtype 2b, which may have antitumor activity (PMID: 23002124, PMID: 16953837, PMID: 24741445). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02948426 | Phase I | Interferon gamma + Peginterferon alfa-2b | Intraperitoneal Infusion of Autologous Monocytes With Sylatron (Peginterferon Alfa-2b) and Actimmune (Interferon Gamma-1b) in Women With Recurrent or Refractory Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer | Terminated | USA | 0 |